Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
Identifieur interne : 000697 ( PubMed/Corpus ); précédent : 000696; suivant : 000698Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
Auteurs : N K AyisiSource :
- East African medical journal [ 0012-835X ] ; 1995.
English descriptors
- KwdEn :
- Antiviral Agents (pharmacology), Cytopathogenic Effect, Viral (drug effects), Didanosine (pharmacology), Drug Evaluation, Preclinical, Ghana, HIV-1 (classification), HIV-1 (drug effects), HIV-1 (pathogenicity), HIV-2 (classification), HIV-2 (drug effects), HIV-2 (pathogenicity), Humans, Microbial Sensitivity Tests, Virus Cultivation, Zalcitabine (pharmacology).
- MESH :
- chemical , pharmacology : Antiviral Agents, Didanosine, Zalcitabine.
- geographic : Ghana.
- classification : HIV-1, HIV-2.
- drug effects : Cytopathogenic Effect, Viral, HIV-1, HIV-2.
- pathogenicity : HIV-1, HIV-2.
- Drug Evaluation, Preclinical, Humans, Microbial Sensitivity Tests, Virus Cultivation.
Abstract
The cytopathicity and susceptibility of prototype HIV-1 [HTLVIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTLVIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTLVIIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.
PubMed: 8904046
Links to Exploration step
pubmed:8904046Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.</title>
<author><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N K" last="Ayisi">N K Ayisi</name>
<affiliation><nlm:affiliation>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1995">1995</date>
<idno type="RBID">pubmed:8904046</idno>
<idno type="pmid">8904046</idno>
<idno type="wicri:Area/PubMed/Corpus">000697</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000697</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.</title>
<author><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N K" last="Ayisi">N K Ayisi</name>
<affiliation><nlm:affiliation>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">East African medical journal</title>
<idno type="ISSN">0012-835X</idno>
<imprint><date when="1995" type="published">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term>
<term>Cytopathogenic Effect, Viral (drug effects)</term>
<term>Didanosine (pharmacology)</term>
<term>Drug Evaluation, Preclinical</term>
<term>Ghana</term>
<term>HIV-1 (classification)</term>
<term>HIV-1 (drug effects)</term>
<term>HIV-1 (pathogenicity)</term>
<term>HIV-2 (classification)</term>
<term>HIV-2 (drug effects)</term>
<term>HIV-2 (pathogenicity)</term>
<term>Humans</term>
<term>Microbial Sensitivity Tests</term>
<term>Virus Cultivation</term>
<term>Zalcitabine (pharmacology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Didanosine</term>
<term>Zalcitabine</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>HIV-1</term>
<term>HIV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cytopathogenic Effect, Viral</term>
<term>HIV-1</term>
<term>HIV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>HIV-1</term>
<term>HIV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Evaluation, Preclinical</term>
<term>Humans</term>
<term>Microbial Sensitivity Tests</term>
<term>Virus Cultivation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The cytopathicity and susceptibility of prototype HIV-1 [HTLVIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTLVIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTLVIIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8904046</PMID>
<DateCreated><Year>1997</Year>
<Month>02</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>1997</Year>
<Month>02</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-835X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>72</Volume>
<Issue>10</Issue>
<PubDate><Year>1995</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>East African medical journal</Title>
<ISOAbbreviation>East Afr Med J</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.</ArticleTitle>
<Pagination><MedlinePgn>654-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The cytopathicity and susceptibility of prototype HIV-1 [HTLVIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTLVIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTLVIIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayisi</LastName>
<ForeName>N K</ForeName>
<Initials>NK</Initials>
<AffiliationInfo><Affiliation>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Kenya</Country>
<MedlineTA>East Afr Med J</MedlineTA>
<NlmUniqueID>0372766</NlmUniqueID>
<ISSNLinking>0012-835X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6L3XT8CB3I</RegistryNumber>
<NameOfSubstance UI="D016047">Zalcitabine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>K3GDH6OH08</RegistryNumber>
<NameOfSubstance UI="D016049">Didanosine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016049" MajorTopicYN="N">Didanosine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015498" MajorTopicYN="N">HIV-2</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014776" MajorTopicYN="N">Virus Cultivation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016047" MajorTopicYN="N">Zalcitabine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year>
<Month>10</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1995</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1995</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">8904046</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000697 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000697 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaGhanaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:8904046 |texte= Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:8904046" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SidaGhanaV1
This area was generated with Dilib version V0.6.31. |